| Short-course radiation plus temozolomide in elderly patients with glioblastoma JR Perry, N Laperriere, CJ O’Callaghan, AA Brandes, J Menten, C Phillips, ... New England Journal of Medicine 376 (11), 1027-1037, 2017 | 1004 | 2017 |
| MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients AA Brandes, E Franceschi, A Tosoni, V Blatt, A Pession, G Tallini, ... Journal of Clinical Oncology 26 (13), 2192-2197, 2008 | 977 | 2008 |
| Immunotherapy response assessment in neuro-oncology: a report of the RANO working group H Okada, M Weller, R Huang, G Finocchiaro, MR Gilbert, W Wick, ... The Lancet Oncology 16 (15), e534-e542, 2015 | 679 | 2015 |
| Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status AA Brandes, A Tosoni, E Franceschi, G Sotti, G Frezza, P Amistà, ... J Clin Oncol 27 (8), 1275-1279, 2009 | 381 | 2009 |
| Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology AA Brandes, A Tosoni, F Spagnolli, G Frezza, M Leonardi, F Calbucci, ... Neuro-oncology 10 (3), 361-367, 2008 | 336 | 2008 |
| Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) AA Brandes, A Tosoni, G Cavallo, R Bertorelle, V Gioia, E Franceschi, ... British journal of cancer 95 (9), 1155-1160, 2006 | 276 | 2006 |
| High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib AMP Omuro, MG Kris, VA Miller, E Franceschi, N Shah, DT Milton, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2005 | 271 | 2005 |
| Glioblastoma in adults AA Brandes, A Tosoni, E Franceschi, M Reni, G Gatta, C Vecht Critical reviews in oncology/hematology 67 (2), 139-152, 2008 | 263 | 2008 |
| Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status AA Brandes, E Franceschi, A Tosoni, F Benevento, L Scopece, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2009 | 257 | 2009 |
| Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) E Franceschi, G Cavallo, S Lonardi, E Magrini, A Tosoni, D Grosso, ... British journal of cancer 96 (7), 1047-1051, 2007 | 237 | 2007 |
| Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent … AA Brandes, A Tosoni, G Cavallo, M Reni, E Franceschi, L Bonaldi, ... Journal of clinical oncology 24 (29), 4746-4753, 2006 | 221 | 2006 |
| Long‐term results of a prospective study on the treatment of medulloblastoma in adults AA Brandes, E Franceschi, A Tosoni, V Blatt, M Ermani Cancer 110 (9), 2035-2041, 2007 | 172 | 2007 |
| Temozolomide as salvage treatment in primary brain lymphomas M Reni, F Zaja, W Mason, J Perry, E Mazza, M Spina, R Bordonaro, ... British journal of cancer 96 (6), 864-867, 2007 | 169 | 2007 |
| Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments AA Brandes, E Franceschi, A Tosoni, ME Hegi, R Stupp Clinical cancer research 14 (4), 957-960, 2008 | 168 | 2008 |
| INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma M Van Den Bent, M Eoli, JM Sepulveda, M Smits, A Walenkamp, ... Neuro-oncology 22 (5), 684-693, 2020 | 160 | 2020 |
| Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial M Reni, W Mason, F Zaja, J Perry, E Franceschi, D Bernardi, S Dell'Oro, ... European Journal of Cancer 40 (11), 1682-1688, 2004 | 143 | 2004 |
| O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for … AA Brandes, E Franceschi, A Tosoni, S Bartolini, A Bacci, R Agati, ... Neuro-oncology 12 (3), 283-288, 2010 | 141 | 2010 |
| Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I–III M Visani, D De Biase, G Marucci, S Cerasoli, E Nigrisoli, MLB Reggiani, ... Molecular oncology 8 (2), 417-430, 2014 | 115 | 2014 |
| Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo … AA Brandes, A Tosoni, E Franceschi, V Blatt, A Santoro, M Faedi, ... Cancer chemotherapy and pharmacology 64, 769-775, 2009 | 111 | 2009 |
| Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial M Reni, S Cereda, M Milella, A Novarino, A Passardi, A Mambrini, ... European Journal of Cancer 49 (17), 3609-3615, 2013 | 105 | 2013 |
